## **Supplementary Materials**

## Estimation of Epidemiological Parameters

Parameters are estimated from the literature and the sources for this are outlined in Table 1. The basic reproduction number, R<sub>0</sub>, was gathered from a systematic review for which the average value was 3.1 and the range of values was 1.9 - 6.5.[1] The infection rate for symptomatic transmissions,  $\beta_1$  was calculated using the  $R_0$  of COVID-19 divided by the infectious period for mild/asymptomatic cases and moderate/severe cases, respectively, taken from.[2-4] The asymptomatic rate in Wanzhou District, China was 20.8%,[5] this gave a value of 0.792 for the asymptomatic rate, the upper bound of 0.815 (asymptomatic rate of 18.5%) is taken from the Diamond Princess cruise ship[6] and the lower bound of 0.568 is taken from the Italian town of Vo,[7] where the asymptomatic rate was 43.2%. The infection rate for symptomatic infection,  $\beta_1$ , was calculated using R<sub>0</sub> and the infectious period assumed from other coronaviruses of 5 days [4]. The reduction in infection rate for asymptomatic patients,  $\alpha$ , was based a model fitted to data from Wuhan.[8] The clearance rate for asymptomatic infection,  $\gamma_1$ , is calculated as the inverse of the infectious period which has an upper bound of 3.48 days, according to data collected in China, [8] a lower bound of 19 days using data on the viral load in asymptomatic patients[5] and the main value is the central point between the two. The clearance rate for symptomatic non-severe and severe cases,  $\gamma_2$  and  $\gamma_3$ , is the inverse of the infectious period, which was estimated as 5 to 7 days[9,10] and 3 to 7 days[11] in the literature. The incubation rate,  $\mu$ , was the inverse of the incubation time which averaged 4.8 days, and ranged from 1 to 14 days[12,13]. The severe case fatality rate,  $\delta$ , ranges from 20.9 percent[14], in South Africa, to 28 percent in China[15]. The relative increase in progression to severe disease in those with HIV/AIDS and/or TB,  $\kappa$ , was assumed to be 2.14 (1.1-2.7) using estimates from South Africa.[14,16]

## **Supplementary Figures**



Figure S1 Projected severe infections over time when parameters are normalized for the age distribution of the population in each country. Areas shaded in grey denote lockdown duration.



Figure S2. Projected severe infections over time when parameters are normalized for the age distribution of the population in each country and the fraction of the under 70-year-old population with HIV/AIDS and or TB. Areas shaded in grey denote lockdown duration.



Figure S3. Peak number of infections by country under the baseline scenario, parameters adjusted by age only.



Figure S4. Peak number of severe infections by country under the baseline scenario, parameters adjusted by age only.



Figure S5. Peak number of infections by country with a moderate lockdown (Scenario 1), parameters adjusted by age only.



Figure S6. Peak number of severe infections by country with a moderate lockdown (Scenario 1), parameters adjusted by age only.



Figure S7. Peak number of infections by country with a hard lockdown (Scenario 2), parameters adjusted by age only.



Figure S8. Peak number of severe infections by country with a hard lockdown (Scenario 2), parameters adjusted by age only.



Figure S9. Peak number of infections by country with a hard lockdown followed by further measures such as social distancing (Scenario 3), parameters adjusted by age only.



Figure S10. Peak number of severe infections by country with a hard lockdown followed by further measures such as social distancing (Scenario 3), parameters adjusted by age only.



Figure S11. Peak number of infections by country under the baseline scenario, parameters adjusted by age and fraction of the under 70-year-old population with TB and/or HIV/AIDS.



Figure S12. Peak number of severe infections by country under the baseline scenario, parameters adjusted by age and fraction of the under 70-year-old population with TB and/or HIV/AIDS.



Figure S13. Peak number of infections by country with a moderate lockdown (Scenario 1), parameters adjusted by age and fraction of the under 70-year-old population with TB and/or HIV/AIDS.



Figure S14. Peak number of severe infections by country with a moderate lockdown (Scenario 1), parameters adjusted by age and fraction of the under 70-year-old population with TB and/or HIV/AIDS.



Figure S15. Peak number of infections by country with a hard lockdown (Scenario 2), parameters adjusted by age and fraction of the under 70-year-old population with TB and/or HIV/AIDS.



Figure S16. Peak number of severe infections by country with a hard lockdown (Scenario 2), parameters adjusted by age and fraction of the under 70-year-old population with TB and/or HIV/AIDS.



Figure S17. Peak number of infections by country with a hard lockdown followed by further measures such as social distancing (Scenario 3), parameters adjusted by age only.



Figure S18. Peak number of severe infections by country with a hard lockdown followed by further measures such as social distancing (Scenario 3), parameters adjusted by age only.



Figure S19. Projected peak infections and peak severe infections when parameters are normalized for the age distribution of the population in each country. Areas shaded in grey denote lockdown duration.



Figure S20. Projected peak severe infections and peak severe infections when parameters are normalized for the age distribution of the population in each country. Areas shaded in grey denote lockdown duration.



Figure S21. Projected peak infections and peak severe infections when parameters are normalized for the age distribution of the population in each country and the fraction of the under 70-year-old population with HIV/AIDS and or TB. Areas shaded in grey denote lockdown duration.



Figure S22. Projected peak severe infections and peak severe infections when parameters are normalized for the age distribution of the population in each country and the fraction of the under 70-year-old population with HIV/AIDS and or TB. Areas shaded in grey denote lockdown duration.

## References

- 1 Park M, Cook AR, Lim JT, *et al.* A Systematic Review of COVID-19 Epidemiology Based on Current Evidence. *J Clin Med* 2020;**9**:967. doi:10.3390/jcm9040967
- 2 Bi Q, Wu Y, Mei S, *et al.* Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *Lancet Infect Dis* 2020;**3099**:1–9. doi:10.1016/S1473-3099(20)30287-5
- Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *Lancet* 2020;**395**:689–97. doi:10.1016/S0140-6736(20)30260-9
- 4 Kissler SM, Tedijanto C, Goldstein E, *et al.* Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. *Science (80- )* 2020;**368**:860–8. doi:10.1126/science.abb5793
- 5 Long QX, Tang XJ, Shi QL, *et al.* Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med* Published Online First: 2020. doi:10.1038/s41591-020-0965-6
- 6 Mizumoto K, Kagaya K, Zarebski A, *et al.* Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. *Eurosurveillance* 2020;25:1–5. doi:10.2807/1560-7917.ES.2020.25.10.2000180
- Lavezzo E, Franchin E, Ciavarella C, *et al.* Suppression of COVID-19 outbreak in the municipality of Vo, Italy. *medRxiv* 2020;:2020.04.17.20053157.
  doi:10.1101/2020.04.17.20053157
- 8 Li R, Pei S, Chen B, *et al.* Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). *Science (80- )* 2020;**368**:489–93. doi:10.1126/science.abb3221
- 9 Prem K, Liu Y, Russell TW, et al. The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study. Lancet Public Heal 2020;5:e261–70. doi:10.1016/S2468-2667(20)30073-6
- 10 Woelfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized cases of coronavirus disease 2019. medRxiv 2020;:2020.03.05.20030502. doi:10.1101/2020.03.05.20030502
- 11 Banerjee R, Bhattacharjee S, Varadwaj PK. Analyses and Forecast for COVID-19 epidemic in India. *medRxiv* 2020;:2020.06.26.20141077. doi:10.1101/2020.06.26.20141077
- 12 Lauer SA, Grantz KH, Bi Q, *et al.* The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann*

Intern Med 2020;172:577-82. doi:10.7326/M20-0504

- 13 Liu T, Hu J, Xiao J, *et al.* Time-varying transmission dynamics of Novel Coronavirus Pneumonia in China. Systems Biology 2020.
- 14 National Institute for Commuicable Diseases. Covid-19 Sentinel Hospital Surveillance Update. 2020.
- 15 Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. *Lancet* 2020;**395**:1014–5. doi:10.1016/S0140-6736(20)30633-4
- 16 Davies M-A. HIV and risk of COVID-19 death: a population cohort study from the Western Cape Province, South Africa. *medRxiv*;:1–21.